How the brain immune protein CLEC7A may affect Alzheimer's
CLEC7A in microglia biology and Alzheimer's disease
Researchers are testing whether changing a brain immune protein called CLEC7A can help brain immune cells clear Alzheimer’s plaques for people with or at risk for Alzheimer’s disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11457046 on NIH RePORTER |
What this research studies
From my point of view, the team is studying a protein called CLEC7A that is active in brain immune cells (microglia) and seems linked to Alzheimer’s. They use lab models of Alzheimer’s (including mice that develop amyloid plaques) to see what happens when CLEC7A is removed or activated, and they measure plaque levels and nerve cell health. The researchers also give a fungal-derived CLEC7A activator in the brain to see if boosting CLEC7A helps microglia clear amyloid. Results may suggest new ways to target microglia to reduce amyloid and protect neurons, which could guide future treatments for people.
Who could benefit from this research
Good fit: This research is most relevant to people living with Alzheimer’s disease or those at high risk who are interested in future therapies that target brain immune cells.
Not a fit: People without Alzheimer’s or those seeking an immediate treatment are unlikely to receive direct benefit from this lab-focused research.
Why it matters
Potential benefit: If successful, this work could point to new ways to boost brain immune cells to remove amyloid and potentially slow Alzheimer’s progression.
How similar studies have performed: Other animal studies have shown that altering microglial receptors can change amyloid clearance, but targeting CLEC7A is a newer approach with promising early results in mice.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Lukens, John R — University of Virginia
- Study coordinator: Lukens, John R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.